Trial
NCT00080626
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI)
Condition
Breast Cancer
Intervention
pegfilgrastim
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-21